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Immune  response  (Ir)  loci  that  map  in  the  I  region  of the  H-2  gene  complex 
regulate  the  capacity  to  generate  an  immune  response  against  numerous  foreign 
antigens  (1).  Loci that  map  in  the  I  region also control  polymorphic~cell surface 
antigens that are expressed in immunocompetent cells (I-region-associated antigens 
or Ia loci)  (2)  and antigens that stimulate T  cell proliferative responses between I 
region disparate strains (lymphocyte-activating determinants or Lad loci)  (3). 
Genetic recombination studies have shown that the I  region can be divided into 
subregions, yet no crossover has yet been detected that allows separation of Ir loci 
from  la  loci  or  Lad  loci.  For  example,  antisera  prepared  between  I-A-subregion- 
incompatible strains react with Ia-I glycoproteins (4), Lad-I -controlled antigens that 
stimulate T  cell proliferative responses (5), and specifically block T  cell responses to 
antigens under control  of the Ir-lA  locus  (6). These observations have  led  to  the 
tentative conclusion that the same locus controls all three traits. However, because 
the  I-A  subregion  represents  a  segment  of chromosome potentially comprised  of 
several  loci,  it  could  be  argued  that  conventional anti-I-A-subregion sera  contain 
multiple specificities. More recent studies with an I-A-subregion mutant strain suggest 
that the Ia-1,  Lad-l, and H-2A loci are identical (7). 
Biochemical and functional studies have significantly advanced our understanding 
of the genetic control ofIa glycoproteins and support the notion that Ia loci, Lad loci, 
and  Ir loci are  equivalent.  Antisera prepared  between  I-E-subregion-incompatible 
strains precipitate three glycoproteins, designated Ea (~33,000 mol wt), Eo (-30,000 
tool wt), and Ii (~31,000 tool wt) (8). The Ea chain is controlled by a locus that maps 
in the I-E subregion, whereas the Ep chain is controlled by a locus that maps in the 
I-A subregion (9). We therefore prefer the designation A~ rather than Et~ for this lower 
molecular weight  chain.  Whether  the  invariant  Ii chain  is  controlled  by  a  locus 
mapping in the I region or elsewhere in the genome remains to be determined. Two 
forms of the ,% chain have been detected biochemically (9). One form is found in the 
cytoplasm of lymphocytes from strains in which no E~ chain is detected. The second 
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Fro.  l.  Biochemieally  described  products  from  the  I-region  of the  H-2  complex.  A=  and  A# 
represent glycoproteins that are encoded in the I-A subregion and are associated on the surface of 
B  lymphocytes  of all mouse strains. The Ae and E= glycoproteins are encoded in the I-A and I-E 
subregions, respectively. Most strains that produce an E= chain express this product in association 
with the A= chain on the cell surface. Most strains that lack an E= chain produce an A~ chain which 
can be found  in  the cell cytoplasm hut  not on the cell surface. Strains which have a surface Ae  b 
chain respond to GLPhe, whereas strains with a surface A~  = chain respond to pigeon cytochrome c 
(responder strains). Strains which lack surface A~ chains do not respond to these antigens (nonre- 
sponder strains). 
form is found on the cell surface of lymphocytes from strains which synthesize an E~ 
chain, and is associated with the Ea chain. These findings are summarized in Fig.  1. 
In some cases, both Ir and Lad phenotypes are associated with the surface appear- 
ance  of the  A~:Ea complex  (9-11).  Immune  responses  to  the  synthetic  polypeptide 
antigen poly(L-glutamic acid,e-alanine,e-phenylalanine)  (GLPHe) 1 correlate with the 
cell  surface  appearance  of  the  A~  b  chain,  whereas  immune  responses  to  pigeon 
cytochrome c correlate with the cell surface appearance of the Ae  k chain  (10,  11).  In 
addition, certain clones of alloreactive T  cells appear to recognize and are stimulated 
by the surface form of the ,% chain  (12). Taken together,  these observations provide 
additional support for the notion that Ia antigens in general, and the A~:E~ complex 
in particular,  are products of Ir loci and serve as Lad antigens.  Evidence that bolsters 
this hypothesis is presented here. 
We  have  produced  a  monoclonal  antibody  that  recognizes  a  conformational  or 
combinatorial  determinant  formed  by  certain  A~:E~  complexes.  This  monoclonal 
antibody blocks  mixed  lymphocyte euhures  (MLC)  directed  at  the  A~:E~ complex 
and blocks T  cell responses to antigens  (GLPhe and pigeon cytochrome c) where the 
response is dependent  on interaction between Ir loci that map in the I-A and the I-E 
1Abbreviatious used in  this paper: B6,  C57BL/6;  BSA, bovine  serum  albumin;  CB6F~, (BALB/c  x 
C57BL/6)F1; CFA, complete Freund's adjuvant;  Con A, concanavalin A; 2-D PAGE, two-dimensional 
polyacrylamide gel eleetrophoresis; EHAA, Eagle's high amino acid; FACS, fluorescence-activated cell 
sorter; FCS, fetal calf serum; FITC, fluorescein isothiocyanate; GLPhe, poly(L-glutamic aeid,L-alanine,t- 
phenylalanine); MIg, mouse immunoglobulin; MLC, mixed lymphocyte culture(s); MLR, mixed lympho- 
cyte reaction(s); NMS, normal mouse serum; PEG, polyethylene glycol; PETLES, peritoneal exudate T 
lymphocyte-enrlched subpopulation; PBS, phosphate-buffered saline; SAS, saturated ammonium sulfate; 
SDS, sodium dodecyl sulfate;  (T,G)-A--L, poly(tyrosine, glutamie acid)-D,L-alanine--L-lysine; TRITC, 
tetramethyl rhodamine isothiocyanate. LERNER,  MATIS, JANEWAY, JR., JONES,  SCHWARTZ, AND MURPHY  1087 
subregions. Thus,  these experiments constitute the strongest evidence to date that at 
least some Ia antigens are products of Lad and Ir loci, and that the Ia loci, Ir loci, and 
Lad loci are identical. 
Materials  and  Methods 
Mice.  (BALB/c  ×  C57BL/6)F1  (CB6F  0  mice  and  the  B10.A,  B10.A(5R)  and  (B10  × 
B 10.A)FI mice used in the peritoneal-exudate-T  lymphocyte-enriched  subpopulation (PETLES) 
experiments were obtained from The Jackson Laboratory, Bar Harbor, Maine. All other strains 
were  bred  and  maintained  in  our  own  animal  facilities at  the  Yale  University School  of 
Medicine, New Haven, Conn. 
Antisera.  Rabbit anti-mouse immunoglobulin (MIg) was prepared by injecting rabbits with 
DEAE-cellulose purified MIg in  complete Freund's adjuvant  intraperitoneally followed by 
intravenous boosting with alum-precipitated MIg. Anti-Thy-l.2 was prepared as previously 
described (13). Anti-I-E  k, I-cdsdG  d serum was produced by hyperimmunizing (B 10 ×  HTI)F1 
recipients with a mixture of B 10.A(3R) lymph node and spleen cells. Monoclonal anti-I-A  k was 
obtained from the hybridoma cell line 10-2.16 (Oi et al. [14]) provided by the Cell Distribution 
Center at the Salk Institute, La Jolla, Calif. 
Fluorescent Reagents.  Fluorescein isothiocyanate (FITC) conjugation of the appropriate an- 
tibodies was performed as described by Johnson et ai. (15). To conjugate monoclonal antibody 
Y-17 with biotin (J. W. Goding. Personal communication.), the antibody was adjusted to  1 
mg/ml in 0.1 M NaHCO3, pH 8.4. Biotin N-hydroxy-succinimide  ester was dissolved in DMSO 
at  1 mg/ml and mixed with Y-17 in a ratio of 1:8 for 4 h. Uncoupled biotin was removed by 
dialysis against phosphate-buffered saline (PBS). Fluorescein- and rhodamine-coupled avidin, 
the  second-step  reagents  for  biotin-labeled antibodies,  were  obtained  from  Vector  Labs, 
Burlingame, Calif. 
Cell Sorting.  A  fluorescence-activated cell sorter (FACS II; BD FACS Systems, Mt. View, 
Calif.) was used to examine antigens on spleen cell surfaces. 
Preparation of Lymphocyte Subpopulation.  T lymphocytes were prepared by passage over Ig anti- 
Ig columns (16). They were >90% Thy-l.2 positive and <3% Ig positive by direct immunoflu- 
orescence. The B cells used in the FACS analysis were obtained by treating spleen cells with 
anti-Thy-l.2 and guinea pig complement to remove the T  cells. 
Immunization and  Fusion Protocol.  B10.A(5R)  spleen cells, suspended at  5 ×  10  6 cells/ml in 
EHAA medium  (17) supplemented with 5% fetal calf serum (FCS), 50 IU/ml  penicillin, and 
50 '#g/ml streptomycin, were stimulated with 5 #g/ml concanavalin A  (Con  A)  (Pharmacia 
Fine Chemicals, Inc., Uppsala, Sweden) and  1 ×  10  7 cells in complete Freund's adjuvant were 
injected into the foot pads and peritoneal cavity of BALB/cByJ mice. 3 wk later, the mice were 
given an intravenous boost of 2 X  107 spleen cells that had been similarly stimulated with Con 
A  in medium that  contained 0.5%  normal mouse serum  (NMS)  in place of FCS. 3 d  after 
boosting, their spleens were removed and the cells fused with the nonsecreting myeloma SP 
2/0 Agl4 (18)  by the procedures of Oi and Herzenberg (19) and Kennett et al. (20).  Spleen 
and myeloma cells were mixed in a ratio of 1:3 and fused with 50% polyethylene glycol 1500 
(PEG). After washing to remove the PEG, the pellet was resuspended to a concentration of I 
×  10  7 total cells/ml in Dulbecco's modified Eagle's medium (DMEM) with 4.5 g/liter glucose 
(Grand  Island  Biological Co.,  Grand  Island,  N.  Y.)  supplemented  with  10%  NCTC  109 
(Microbiological Associates, Walkersville, Md.),  15%  FCS,  10  mM  Hepes,  1  mM  sodium 
pyruvate, 2 mM L-glutamine, 50 IU/ml penicillin, 50 #g/ml streptomycin, 0.25 #g/ml ampho- 
tericin, and Littlefield's (21)  concentrations of hypoxanthine (1.0  ×  10  -4 M)  and thymidine 
(1.6 ×  10  -5 M).  100 #1 of the suspension was added to wells of flat-bottomed microtiter plates 
(3040;  Falcon Labware, Die. of Beeton, Dickinson & Co., Oxnard, Calif.). The hybrids were 
fed the above media supplemented with aminopterin, 8  ×  10  -7 M,  the day after fusion and 
then every 3-4 d until the clones were screened. 
Screening Procedures.  Supernates from wells with macroscopic clones were screened using a 
microcytotoxicity  assay described previously (22) and by a radioimmunoassay (23). In the latter 
method,  the  binding  sites  of flexible polyvinyl microtiter  plates  (Cooke  Engineering  Co., 
Alexandria, Va.) were blocked with  1% bovine serum albumin (BSA) in PBS for 1 h at 4°C. 1088  MONOCLONAL ANTIBODY  AGAINST AN Ir GENE  PRODUCT? 
The plates were washed three times with PBS and 50 #l of supernate from the corresponding 
wells of the culture plate were added. Spleens from the appropriate test strains were removed 
and the erythrocytes lysed by hypotonic shock. 10 #1 of spleen cells suspended at 5 ×  107 cells/ 
ml in PBS with 5% FCS and 0.1% sodium azide were layered over the supernates and allowed 
to  incubate for  1 h  at  4°C.  The plates were washed by centrifugation for 2  min  at  400 g, 
flicking out the supernate, filling the wells with PBS followed by a second spin and flick. The 
pellets were  resuspended  by  vortexing and  25,000  cpm  of nSI-protein A  (Pharmacia  Fine 
Chemicals, Div. of Pharmacia, Inc., Piscataway, N. J.) in 50 #1 of PBS was then added. After 
an additional 1 h  at 4°C,  the plates were washed six times as above and dried under a  heat 
lamp. Radioautography (24) was performed with Kodak RPR x-ray film (Eastman Kodak Co., 
Rochester, N. Y.) and an intensifier screen (Cronex Lightning Plus, E. I. DuPont de Nemours 
& Co., Wilmington, Del.) mounted on the bottom of the plate. The films were developed after 
a  12-h exposure at -70°C. Positive wells appeared as dark spots against a faint background. To 
obtain more quantitative information, the wells were cut out and counted in a gamma counter 
(Uitrogamma 1280; LKB Produkter, Bromma, Sweden). 
Purificatzon of Monoclonal Antibody.  Cells from one of the wells, termed Y- 17, whose supernate 
was  active in  both  the  cytotoxicity and  cell-binding screening procedures,  were cloned by 
limiting-dilution. Supernates from all of the wells with subsequent  growth showed activity. 
Cultures were expanded, and cells were frozen for future use or were injected into the peritoneal 
cavities of Pristane-treated BALB/c mice to generate ascites. Antibody from the ascites fluid 
was isolated with two successive precipitations using 45% saturated ammonium sulfate followed 
by dialysis against PBS.  (Precipitation with sodium sulfate resulted in  the complete loss  of 
antibody activity.) 
Determination of Immunoglobulin Class.  The  antibody fraction obtained  above was  further 
purified by IgG class specific elution from a  Protein A-Sepharose column (25).  The fractions 
were monitored with a Uvicord spectrophotometer (LKB Produckter) and collected. They were 
assayed for activity as described and subjected to Ouchterlony analysis against class-specific 
goat  anti-MIg  (Meloy Laboratories Inc.,  Springfield, Va.).  The  antibody was  found  to  be 
complement fixing, protein A  binding, and of the IgG2b glass by both protein A-Sepharose 
chromatography and Ouchterlony analysis. 
Radiolabeling, Detergent Extraction, Immunoprecipitation, and  Two-Dimensional Polyacrylamide Gel 
Electrophoresis (2-D PAGE) of la Antigens.  Proteins were immunoprecipitated from Nonidet- 
P40 detergent extracts of [~S]methionine-labeled spleen cells according to published procedures 
(8). Extract from 107 cells was mixed with 100 #1 of Y-17 culture supernate or with 30 #1 of one 
of the following sera: BALB/c normal mouse serum, C3H anti-CSW (anti-H-2b), or B 10.A(18R) 
anti-B 10.A(5R) (anti-JkEkCaSa). Antigen-antibody complexes were isolated using Staphylococcus 
aureus bacterial adsorbent (IgG Sorb; The Enzyme Center, Boston, Mass.). Immunoprecipitated 
proteins were separated by 2-D PAGE, using nonequilibrium pH gradient electrophoresis (8, 
26) for the charge separation in the first-dimension gels. After the second dimension separation 
by sodium dodecyl sulfate (SDS) slab gel eleetrophoresis, the gels were processed for radioau- 
tography using Kodak NS-2T No Screen x-ray film. 
MLC.  MLC were performed as described previously (27).  Briefly, responder T  cells were 
prepared by passing spleen cells over Ig anti-Ig columns. Stimulator spleen cells were treated 
with mitomyein C, washed thoroughly, and incubated with Y-17 or medium alone for 1 h at 
37 ° C. 5 ×  105 or 106 responder and 5 ×  10  s stimulator cells were cultured in triplicate, with 0.2 
ml of EHAA medium supplemented with 0.5% fresh NMS or 5% FCS in Falcon 3040 microtiter 
plates. Cultures were pulsed after 5 d with 1 #Ci of [3H]thymidine ([3H]TdR; 50-60 Ci/mmol; 
New England Nuclear, Boston, Mass.) for 5 h. The cells were harvested onto glass fiber strips 
with a MASH II harvester (Microbiological Associates) and samples counted in a scintillation 
counter (Beckman Instruments, Inc., Fullerton, Calif.). The data are expressed as mean counts 
per minute; SEM were <10%. 
Effect of Monoclonal Antibody on T Cell-proliferative Response to Antigen 
ANrmEys.  Pigeon cytochrome c was purchased from the Sigma Chemical Corporation, St. 
Louis, Mo. and, subsequently purified by column chromatography on carboxymethyl cellulose 
to remove contaminants such as polymeric and deamidated forms of the molecule (28). 
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gift of Dr. Alan Rosenthal,  Merck, Sharp and  Dohme,  Rahway, N. J.  The branched-chain 
synthetic amino acid polymer poly(tyrosine, glutamic acid)-n,L-alanine--L-lysine  [(T,G)-A--L] 
(lot MC6)  was also purchased from Miles-Yeda, and was the generous gift of Drs.  Howard 
Dickler and Alfred Singer, National Cancer Institute, National Institutes of Health, Bethesda, 
Md. 
IMMUNIZATIONS.  Mice were immunized in  the hind foot pads with  30 #g GLPhe,  50 #g 
(T,G)-A--L, or 30 #g pigeon cytochrome c emulsified 1:1 in complete Freund's adjuvant that 
contained  1 mg/ml  of killed Mycobacterium tuberculosis, strain  H37  Ra  (Difco  Laboratories, 
Detroit, Mich.) in a total vol/animal of 0.1 ml. 
CELL CULTURES.  The preparation of PETLES and their in vitro culture with antigen are 
described in detail elsewhere (29).  Briefly, 100 #l of Eagle's high amino acid (EHAA) medium 
supplemented with 10% FCS and that contained 1 ×  105-2 ×  105 PETLES were placed in each 
well of a sterile, U-bottomed microculture plate. To assay lymph node proliferation, draining 
inguinal and popliteal lymph nodes were aseptically removed from animals 8 d after immuni- 
zation, teased, screened to form a single cell suspensions, and passed over nylon wool columns 
in medium that contained 5% FCS. Eluted cells were then plated in 100 pl at 4 ×  105 cells/well 
in flat~bottomed 96-well microtiter plates in EHAA medium supplemented with 10% FCS. 
An SAS precipitate of ascites containing Y-17 at 12 mg/ml in 0.1% sodium azide was diluted 
1:20  in  complete medium  supplemented with  10%  FCS and  then  exhaustively dialyzed to 
remove the azide. To assess blocking of antigen-induced T cell proliferation, 40 #1 of the diluted 
and dialyzed monoclonal antibody was added to wells, which then received either antigen or 
medium alone, to achieve a  final dilution of Y-17 of 1%  (vol:vol). The antigens were then 
added to the cultures to achieve the following final concentrations in a total vol of 200 #I/well: 
GLPhe,  50 #g/ml;  pigeon cytochrome c,  30 pg/ml;  (T,G)-A--L, 50 #g/ml;  purified protein 
derivative from M. tuberculosis (PPD) (Connaught Medical Research Labs, Willowdale, Ontario, 
Canada), 20 #g/ml. Medium without antigen served as a nonstimulated control. 
The cultures were then incubated at 37 ° for 5 d. Stimulation was assessed by measuring the 
incorporation of a  1-#Ci pulse of [3H]TdR  16-18 h before harvesting the cultures. Determina- 
tions were done in triplicate and the data expressed as the difference between antigen-stimulated 
and nonstimulated responses (Acpm). The standard errors for the Acpm values were derived 
from  the square root of the sum of the squares of the standard errors of the mean  antigen- 
stimulated and nonstimulated responses. Percent inhibition by Y- 17 was calculated by dividing 
the Acpm in the presence of Y-17 by the Acpm in its absence, subtracting the ratio from 1 and 
multiplying by 100. 
To assess the effect of Y-17-plus-complement-induced killing on subsequent antigen-induced 
proliferation, nylon wool-purified, antigen-primed lymph node cells were incubated in a  1:20 
dilution of the monoclone at  l0  s cells/ml for 30 min at 4°C. The cells were then washed twice 
and incubated at the same concentration in a  1:10 dilution of rabbit complement at 37°C for 
another 30 min. The cells were washed twice again, resuspended in EHAA medium with 10% 
5  FCS,  and  added  to  microtiter plates at  4  ×  10  living cells  (assessed by  trypan blue  dye 
exclusion) per well, either in the presence of antigen or of medium alone. 
Results 
Y-17 Reacts with an H-2-controlled Antigen (Table I).  As judged by both cytotoxicity 
and  radioimmunoassay, Y-17  reacts with  immunizing strain B10.A(5R)  spleen cells 
(50% titer, -  10 ~) but not recipient strain BALB/c spleen cells (Table I). Roughly 55% 
of splenic lymphocytes are lysed in the presence of complement. To determine whether 
Y-17  reacts with  an  H-2- or non-H-2-controlled antigen, strain  B10.D2  was  tested. 
This strain shares the H-2 a haplotype with BALB/c and the non-H-2 B 10 background 
with  B10.A(5R).  Failure of Y-17  to react with  B10.D2  maps the locus that  controls 
the determinant to the H-2 complex. (Table I). 
Y-17 Reacts with an I-Region-controlled  Determinant  (Table lI).  As shown in Table II, 
Y-17 reacts with only two (H-2 k and H-2 r) of the eight independent H-2 haplotypes 
tested. Positive reactions with recombinant strains BI0.A, A.TL, and B10.AQR, and 1090  MONOCLONAL  ANTIBODY  AGAINST  AN  Ir GENE  PRODUCT? 
TABLE  I 
Y-17 Reacts with an H-2-controUed Antigen 
50%titer* 
Strain  H-2 haplotype 
Cytotoxic  RIA 
BALB/c  d  0  0 
B10.A(5R)  i5  105  10  ~ 
BI0.D2  d  0  0 
* Spleen  cells  tested  with  Y-17 using  assays  described in  Materials  and 
Methods. 
TABLE  II 
Y-17 Reacts with an I-region-controlled Antigen 
A. Independent H-2 haplotypes 
Strain 
H-2 
haplo- 
type 
K  A  B  J  E  C  S  G  D  50%titer 
Ae:Ea 
com- 
plex  ex- 
pressed 
on  sur- 
face 
B10, A.BY, BALB.B  b 
B10.D2, BALB/c  d 
BI0.M, A.CA  f 
B10.BR, BALB.K, CBA/N  k 
B10.P  p 
BI0.G  q 
B 10.RIII  r 
B 10.S, A.SW  s 
bbbbbbbbb  0 
d  d  d  d  d  d  d  d  d  0  d:d 
fffffffff  0 
k  k  k  k  k  k  k  k  k  105  ~* 
p  p  p  p  p  p  p  p  p  0  p:p 
qqqqqqqqq  0 
rrrrrrrrr  10  5  [] 
SSSSSSSSS  0  -- 
B. Recombinant H-2 haplotypes 
B10.A, A/Sn 
A.AL 
C3H.OL 
C3H.OH 
B10.A(2R) 
B10.A(4R) 
B10.A(3R) 
B10.A(5R) 
B10.A(18R) 
A.TL 
B10.S(7R), A.TH 
B 10.HTT 
B 10.S(9R) 
B10.S(SR) 
B10.AQR 
B 10.T(6R) 
B10.F(13R) 
A.TFR5 
a  k  k  k  k  k  d  d  d  d  l0  s 
al  k  k  k  k  k  k  k  k  d  105 
ol  d  d  d  d  d  d  k  k  k  0  d:d 
o2  d  d  d  d  d  d  d  d  k  0  d:d 
h2  k  k  k  k  k  d  d  d  b  105 
h4  kkbbbbbbb  0 
i3  b  b  b  b  k  d  d  d  d  10  ~ 
i5  b  b  b  k  k  d  d  d  d  105 
i18  b  b  b  b  b  b  b  ?  d  0 
tl  skkkkkkkd  10  5 
t2  ssssssssd  0  -- 
t3  sssskkkkd  1~-105 
t4  ss  kkdddd  1~-10  ~ 
asl  kk  sssss  0  -- 
yl  qkkkkdddd  10  ~ 
y2  qqqqqqq  d  0  -- 
?  nnnnnnbbb  0  n:n 
ap5  ff  kkkkd  0  -:k 
* Boxed Ae:E~ complex~ associated with killing of cells with Y-17 plus complement. 
negative  reactions  with  recombinant  strains  A.TH,  B10.S(7R),  and  B10.T(6R), 
localize control of this determinant  between the K  region and  I-C subregion. Based 
on  current  Ia  specificity charts  with  independent  H-2  haplotypes,  the  specificity 
detected by Y-17  is similar to Ia. 19  (30).  However, because the Ia. 19-positive recom- LERNER,  MATIS,  JANEWAY,  J~.,  JONES,  SCHWARTZ,  AND  MURPHY  1091 
binant strains  B10.A(4R)  and B10.S(8R)  do not react with Y-17, we designate this 
new specificity Ia.m.44  (P. Demant. Personal communication.). 
Y-17  Reacts  with  an  Antigen  That  is  Under Two-Gene  Control (Table  III).  At  first 
glance, data presented in Table II suggested that Y-17 reacts with an I-Ek-subregion - 
controlled antigen. However, the observation that strain A.TFR5,  which carries the 
LE  a subregion  and expresses  low but detectable  levels  of E~  k chains  (31),  failed  to 
react with our monoelonal antibody raised the possibility that Y-17 was specific  for 
a  hybrid  antigen.  To  test  this  possibility,  we  tested  Y-17  on  cells  from  several  FI 
hybrid crosses prepared between strains, neither of which reacted with Y-17. 
For example, strains B6 and BALB/c both failed to react with Y-17. In contrast, a 
strong reaction was  observed with  CB6F1  hybrids  (Table  III).  A  similar  result  was 
obtained with several other FI hybrids, including (B 10.S[7R] ×  A.TFR5)F1. However, 
(B10.T[6R]  X A.TFR5)Fa  animals did not react with Y-17, demonstrating that gene 
interaction  between  non-H-2-1inked  genes  can  not  account  for  expression  of  the 
determinant  detected  by  Y-17.  We  conclude  that  Y-17  reacts  with  a  determinant 
whose expression is generated by interaction between two I region loci. 
Evidence  That  Y-17 Reacts with Certain Ae.'E,~ Complexes (Fig.  2).  To determine the 
biochemical nature of the determinant detected by Y- 17, we labeled B6, BALB/c and 
CB6F1 spleen cells biosynthetically with [aSS]methionine, and examined the molecules 
TABLE  III 
Y-236 Reacts with an Antigen  That Is Under Two-Gene Control 
Allele expression*  A.:E~ com- 
Strain  50% titer  plex de- 
E,~ chain  tected  A, chain 
B6  b  Cytoplasm  --  None  0  -- 
BALB/c  d  Surface  d  Surface  0  -- 
F1  h,d  Surface  d  Surface  10  s  b:d 
B 10.S  s  Cytoplasm  --  None  0  -- 
B 10.D2  d  Surface  d  Surface  0  -- 
F1  s,d  Surface  d  Surface  10 5  s:d 
B 10.A(4R)  k  Cytoplasm  --  None  0  -- 
A.TFR5  --  None  k  Surface  0  -- 
F1  k  Surface  k  Surface  10  s  k:k 
B 10  b  Cytoplasm  --  None  0  -- 
A.TFR5  --  None  k  Surface  0  -- 
Fl  b  Surface  k  Surface  10  s  b:k 
B 10.S(7R)  s  Cytoplasm  --  None  0  -- 
A.TFR5  --  None  k  Surface  0  -- 
F~  s  Surface  k  Surface  10  s  s:k 
B 10.T(6R)  --  None  --  None  0  -- 
A.TFR5  --  None  k  Surface  0  -- 
F1  --  None  k  Surface  0  -- 
* E~  a'~'p'r chains, but not E,,  b'f'q'~ chains detected serologically and biochemically. A,  b'd't'p'~" chains, but not 
A,  f'q chains detected biochemically. A,  b'a'k'p~ chains found in the cytoplasm of cells from strains carrying 
I-E  b'f'q'j and on the cell surface of strains carrying I-E  a'gpx. Quantitatively less E~  k chains found on the cell 
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FIG.  2.  2-D PAGE analysis ofIa immunoprecipitates. Extracts from [~E]methionine-labeled spleen 
cells were immunoprecipitated  with normal mouse serum  (a, d, g, and j), C3H anti-CSW (anti-H- 
2  b)  (b), B10.A(18R)  anti-B10.A(SR)  (anti-JkE~ds n)  (e,  h, and k), and Y-17 supernate  (c, f, i, and 
1). Each panel represents the immunoprecipitate from the extract of 4 X  106 cells. Radioautographic 
exposures of the gels were for 21  d. The position of actin is indicated by the letter "a" in the upper 
panels. The identity of the polypeptide chains is indicated,  based on previous findings (8,  9). The 
significance of the spots marked by the large arrows in i is discussed in the Results. LERNER, MATIS, JANEWAY, JR., JONES, SCHWARTZ, AND MURPHY  1093 
precipitated from cell lysates with Y-17 by 2-D PAGE (Fig.  2). No molecules were 
precipitated from B6 or BALB/c lysates; thus, Y-17 does not react with A~  b, Aa  b, or 
the cytoplasmic form of the A~  b chain (B6), or the cell surface form of the A~  a chain 
associated with the E~  a chain (BALB/c), or Ii chains from either strain. In contrast, 
the E,  a chain, the cell surface form of the A~  b chain, and the Ii chain were precipitated 
from CB6F1 lysates. Because Ii chains were found in all Ia precipitates (8), these results 
demonstrate that  Y-17 reacts with a  determinant formed by the association of A~  b 
and E~  a. 
In sum, Y-17 reacts with a  conformational or combinatorial determinant formed 
by the following A~:Ea complexes: A~b:E,  a (e.g., CB6F1); A~b:E,  k (e.g., B10.A[SR] and 
[B10  ×  A.TFR5]F1);  A~k:E~  k  (e.g.,  B10.A  and  [B10.A(4R)  X  A.TFR5]F0;  A~r:E~  r 
A~:  ~  (e.g.,  B10.HTT,  [B10.S(7R)  ×  A.TFR5]Fx);  and  Ae':E,  a  (e.g.,  B10.Rlll);  * E  k 
(e.g., [B10.S ×  B10.D2]FI). Y-17 does not react with the cytoplasmic form of the A~  b 
(e.g., B10), A~  k (e.g., B10.A[4R]), or Ao  * (e.g., B10.S[7R]) chains, the cell surface form 
of free Ea  k chains (e.g., A.TFR5), or complexes formed by A~a:E~  a (e.g., BALB/c and 
B10.D2), or A~P:E, p (e.g., B10.P) chains. 
In Addition to the Ae and E~ chains, Y-17 Precipitates a Third I-Region-controlled Molecule 
(Fig. 2).  Studies of precipitates obtained from CB6Fx hybrids suggested that a third 
I-region-controlled molecule was precipitated by Y- 17. Because relatively low amounts 
of this molecule were precipitated in heterozygous animals, we examined lysates from 
homozygous B10.A(5R) and B 10.A animals. A~  b, E,  k, and molecules that exhibited a 
2-D  PAGE  pattern  indistinguishable  from  A~  b were  precipitated  with  B10.A(5R) 
lysates (Fig. 2). A~  k, E~  k, and molecules that exhibited a  2-D PAGE pattern indistin- 
guishable from A~  k, were precipitated with B10.A lysates (data not shown).  No Aa 
chains were detected in either precipitated lysate. Note that conventionally prepared 
anti-I-E-subregion  sera  precipitated  only the  A~  and  E~  chains.  The  third  chain, 
therefore,  does  not  nonspecifically  associate  with  the  A~:E~ complex  during  the 
extraction procedure. Although it is clear that this third chain is controlled by an H- 
2-1inked locus  (2-D PAGE patterns  from B10.A(5R)  and B10.A differ), we are not 
sure whether the third chain is the A, chain or a new Ia molecule (X). 
Y-17 Reacts with a Subset of B Lymphocytes and with Non- T and Non-B Cells (Table IV and 
Fig. 3).  Previous studies have shown that anti-I-A or anti-I-E sera react with >95% 
of splenic B lymphocytes (32), and that the A,, Ap, E,, and Ae chains are synthesized 
by these B lymphocytes (33). In contrast, the maximum percent of spleen cells killed 
or stained by Y-I 7 was always less  than the number of cells killed by conventional 
anti-I-E reagents, a  monoclonal anti-I-A antibody, or stained with FITC-anti-MIg. 
Representative data  for spleen cells from individual  mice are shown  in Table IV. 
Furthermore, spleen cells from 5R  mice stained  with both tetramethyl rhodamine 
isothiocyanate  (TRITC)-anti-mouse #-chain  antibody and  biotin-conjugated  Y-17 
plus  FITC-conjugated avidin  revealed  ~20%  of #-chain-bearing cells that  did  not 
bind Y-17, and occasional (~5%) cells that were Y-17 positive, #-chain negative. 
In addition to cytotoxicity and conventional fluorescence microscopy, a FACS was 
used to examine anti-Thy-1.2-and-complement-treated spleen cells from a pool of five 
CB6F1 mice. As shown in Fig. 3, cells to the right of the arrow were positive by FACS 
analysis. By these criteria, 3% of the unstained cells had fluorescent intensities above 
background levels and 82% of the cells labeled with anti-MIg were positive. Only 54% 
of these  same  cells  that  had  been  stained  with  Y-17  fell  above  this  fluorescence 1094  MONOCLONAL ANTIBODY  AGAINST AN Ir GENE  PRODUCT? 
TAnLe  IV 
Y-17 Reacts with a Subset of B  Cells 
Spleen cells 
from* 
Percent spleen cells killed by~  Percent spleen cells 
stained by 
C'  Anti-  Y-17  Y- 17  Anti-I-A§  Anti-I-Ell  alone  MIg 
CB6FI  40  --  63  6  70  55 
38  --  64  6  65  48 
B 10.A(5R)  60  --  68  5  70  60 
52  --  64  6  73  54 
B10.A  60  72  72  6  71  62 
52  58  61  6  61  46 
* Spleen cells from individual mice centrifuged on Ficoll-Hypaque. 
:~ Plateau cytotoxic kill using rabbit complement (C'). 
§ Hybrid 10-2.16, anti-I-A  k (anti-Ia-I  7). 
II (B10 × HTI)F~ anti-B10.A(3R) (anti-EkCaSdGa). 
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Flo.  3.  FACS profile of Y-17 fluorescent anti-Thy-1.2-treated  spleen ceils. Viable anti-Thy-1.2  + 
C'-treated CB6F1 spleen cells were examined unstained  (A), stained with biotin-Y-17 followed by 
FITC-avidin (B), or stained with FITC-anti-MIg (C). Arrow gives threshold selected to discriminate 
positive from negative cells. 
threshold,  although  no clear separation of Y-17-positive from  Y-17-negative B  cells 
was seen using the FACS. All of these results taken together support the conclusion 
that the determinant detected by Y-17 is expressed on a  subset of B lymphocytes. An 
alternate interpretation is that all B cells bear the determinant detected by Y-17, but 
as indicated by the FACS profile, some of these ceils have too little antigen on their 
surface to be killed or visually stained by Y-17. 
It is known that some T  cells (34-36) and some spleen cells (which lack both B and 
T  cell  markers)  (37)  react  with  anti-I-A  or  anti-I-E  subregion  sera  (38).  In  two 
experiments, column-purified T  cells were examined with FITC-anti-Thy-l.2, FITC- 
anti-MIg, and  biotin-conjugated Y-17  followed by the addition of FITC- or rhoda- 
mine-labeled avidin. In the first experiment, 94% of the cells were Thy-1.2 positive, 
<  1% Ig positive, and 7% of the total cells were stained with the monoclonal antibody. 
In  the  second  experiment,  in  which  B  cell  contamination  was  3%,  the  cells were 
double-labeled with  FITC-anti-Thy-l.2  and  a  rhodamine-avidin-biotin-Y-17 com- 
plex. These cells showed 91% stained only with anti-Thy-l.2, 6% only with Y-17, and LERNER,  MATIS, JANEWAY, JR.,  JONES,  SCHWARTZ, AND MURPHY  1095 
none with both  conjugates.  Y-17  therefore appears  to  react  with a  Thy-1.2-negative 
and  Ig-negative set of cells as well as with B  cells. We have not detected the antigen 
on T  cells. 
C57BL/6 Anti-B10.A(5R) and B10.A(4R) Anti-BIO.A(2R) MLC Responses Are Blocked 
by  Y-17 (Fig.  4 and Table  V).  I-region-encoded  determinants,  especially in  I-A and 
I-E have been shown to stimulate  in MLC  (3, 5).  Recently, Fathman  et al.  (12)  have 
observed  a  mixed  lymphocyte  reaction  (MLR)  apparently  dependent  on expression 
of the A~:E,, complex on  the stimulator  cells. We have examined  the ability of Y-17 
to block the MLR  between responding T  cells from B6 mice which do not express the 
cell surface  form  of the A~  b chain  and  stimulator  5R  spleen  cells which  express  the 
Aeb:Ea  k  complex  on  the  cell  surface.  5R  also  differs  from  B6  at  the  I-J  and  I-C 
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Flo.  4.  Y-17 specifically blocks B6 anti-Bl0.A(5R) (5R) MLC. An MLC between B6 responder T 
cells and mitomycin-C-treated spleen cells from CB6F], BALB/c, 5R, and syngeneic  B6 animals 
was performed in the presence of various dilutions of Y-17. The response  to 5R, but not that to 
other stimulator cells was inhibited by Y-17. 
TAnLE g 
Y-17 Inhibits the Response of BIO.A(4R) T Cells to BIO.A(2R) Stimulators 
MHC  A,:E,  MIX2 response with Y-17 at dilution* 
Stimulator  complex 
I  expressed 
spleen cells K  S G D  on cell  Control  10  -2  10  -a  10-'  10  -5  Block? 
A B J  E C  surface 
B10.A(4R)  k  k  b b b  b  b  b  b  --  (5,800) (7,400)  (7,000)  (8,900)  (6,400)  negative 
control 
BI0.A(2R)  k  k  k k k  d  d  d  b  k:k  22,200  -800  -600  3,100  25,800  yes 
B10.A(5R)  b  b  b k k  d  d  d  d  b:k  266,600  302,700  216,900  210,600  272,200  no 
B10  b  b  b b b  b  b  b  b  --  101,300 179,200  152,700  121,200  165,800  no 
* Control counts in groups with BI0.A(4R) stimulators have been subtracted from experimental counts. 1096  MONOCIA3NAL ANTIBODY AGAINST AN  Ir GENE  PRODUCT? 
subregions and the D  end of the H-2 complex. The results in Fig. 4 show that Y-17 
blocks ~66%  of the B6 response to 5R out  to a  dilution of 10  -4.  The responses to 
BALB/c  and  to  CB6F1  are  not  affected,  even  though  Y-17  reacts  with  A~b:E~  d 
complexes on the CB6F1 stimulator cells. This serves as an important control, because 
it suggests that Y-17 is not simply killing stimulator cells. Moreover, Y-17 completely 
inhibits  the  response  of B10.A(4R)  T  cells  to  BI0.A(2R)  stimulators  (Table  V). 
B10.A(2R) expresses the A~k:E~  k complex on the cell surface, whereas B10.A(4R) has 
the A~  k chain in the cytoplasmic form only. The response of B 10.A(4R) to B 10.A(5R) 
is not affected by Y-17 even though Y-17 can bind to the stimulator cell. This result 
could be explained by proposing that the B 10.A(4R) anti-B 10.A(5R) MLR is directed 
primarily against  the A~b:Ap  b complex, whereas  the  B6  anti-5R  MLR  is  directed 
primarily  against  the  A~b:E~  k complex.  Thus,  Y-17  specifically inhibits  responses 
directed primarily at A~b:E~  k complexes and not A~b:Ap  b complexes. 
Y-17 Inhibits  Proliferative Responses to  GLPhe  and Pigeon Cytochrome c.  The  immune 
responses to the synthetic polypeptide GLPhe and the protein antigen pigeon cyto- 
chrome c are controlled by interacting loci that map in the I-A and I-E subregions. 
The appearance of the A~b:E~  k or the Aek:E~  k complex on the cell surface correlates 
with the ability to respond to GLPhe (10)  or pigeon cytoehrome c (11), respectively. 
Because Y-17 recognizes both of these chain combinations, we examined the ability 
of Y-17  to  block  antigen-induced  proliferation of PETLES or  nylon wool-passed 
lymph node T  cells  (Table VI).  The proliferative responses to GLPhe and  pigeon 
cytochrome c were consistently inhibited 80-100% in the presence of 1% Y-17. Y-17 
had no effect on the proliferative response to (T,G)-A--L and no significant effect on 
the  medium  controls,  demonstrating  that  the  antibody  was  not  nonspecifically 
inhibitory. The proliferative response to PPD was repeatedly inhibited by 10-30% in 
the presence of Y- 17. This result is consistent with our previous blocking studies using 
anti-Ia.7 sera (38) and suggests that the weak inhibition of the proliferative response 
to PPD represents the involvement of A~:E~ complexes in the presentation of some 
determinants on this antigen.  In contrast, the complete absence of any significant 
inhibition of proliferation to (T,G)-A--L, the response to which is under the control of 
an Ir gene(s) mapping in the I-A subregion, indicates that the A~b:E~  k complex is not 
involved in the presentation of this antigen. 
Pretreatment of the responding B I0.A(5R)  lymph node cells with a  1:20 dilution 
of Y- 17 plus rabbit complement before culture reduced the proliferative responses to 
(T,G)-A--L,  PPD,  and  GLPhe  by  50-70%  (data  not  shown),  suggesting  that  the 
specific inhibition seen in the blocking experiments could not be attributed to selective 
elimination  of an  antigen-presenting cell subpopulation.  Thus,  Y-17  inhibits  only 
those antigen-specific proliferative responses controlled by interacting Ir genes that 
map in the I-A and I-E subregions. These results are the first unequivocal demonstra- 
tion  in  the  antigen-specific  proliferative  assay  that  the  inhibitory  component  in 
blocking antisera is, in fact, an Ia-specific antibody rather than an antibody directed 
against either a closely-linked Ir gene product or against the actual T cell receptor for 
self-Ia (39).  These results therefore strongly suggest that Ia molecules are in fact the 
Ir gene products. 
Discussion 
We have produced a  monoclonal antibody, Y-17, which reacts with a  conforma- 
tional or combinatorial determinant formed by the association of the I-A-subregion- LERNER,  MATIS, JANEWAY, J~t., JONES,  SCHWARTZ,  AND MURPHY 
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controlled Ae chain and  the I-E-subregion-controlled E~ chain  (Fig.  2).  Cytotoxic, 
conventional fluorescence, and FACS studies suggest that the determinant recognized 
by Y-17 is expressed on a  subpopulation of splenic B cells as well as on non-T and 
non-B splenic cells. In functional experiments, Y-17 blocks MLC between responder 
T  cells from strains that lack cell surface A~:E, complexes and stimulator cells from 
strains which express this complex. In addition, Y-17 completely inhibited the antigen- 
induced  T  cell  proliferative  response  to  GLPhe  and  pigeon  cytochrome c;  these 
responses are under dual-Ir-gene control and correlate with the expression of certain 
A~:E~ complexes on antigen-presenting cell surfaces. 
Two additional studies show that association of I-A- and I-E-subregion controlled 
products results in the expression of a serologically detected antigen. Based on strain- 
distribution patterns, the specificity detected by Y-17 is different from that described 
by Harris and Deloviteh (40), and similar to that described by LaFuse et al.  (Ia.22) 
[41]. Because preliminary data with certain F1 hybrid combinations suggest that the 
specificity detected by Y-17 is not Ia.22 (D. B. Murphy. Unpublished observations.), 
we provisionally designated this specificity Ia.m.44. These observations, coupled with 
those  of Fathman  and  Hengartner  (12)  in  MLC  reveal  that  numerous  antigenic 
specificities can be generated by the association of two I-region molecules. 
The observation that a  third I-region-controlled chain (X) is precipitated with Y- 
17 is intriguing. Because conventionally prepared anti-I-E-subregion sera precipitate 
only the A~ and E~ chains, the X  chain does not nonspecifically associate with Ae:E,, 
complexes. Based on 2-D-PAGE, the X  chain is indistinguishable from the A~ chain. 
Peptide map analysis of the X  chain is in progress to determine whether it is indeed 
the  A~ chain or a  new chain.  Until  this  result  is  obtained,  the possible hybrid Ia 
antigen associations include A~:Ag, Ae:E~, and A~:X. These combinatorial Ia antigens 
(the number of which would be much amplified in heterozygotes) could have broad 
implications for immune response gene function. 
The two functional studies  presented bear on the relationship of I-region linked 
immune response and Lad genes to Ia antigens. Ia antigens in general, and the A~:E~ 
complex in particular, are known to be recognized by T cells (5, 6, 34). Y-17 effectively 
blocks this recognition, both in response to allogeneic A~:Ea complexes and in response 
to nominal antigen associated wih self Ae:E, complexes. The appearance of certain 
Ae:E~ complexes on the cell surface correlates with the ability of T  cells from a given 
strain of mouse to respond to pigeon cytochrome c (11) and with the ability of certain 
F1 antigen-presenting cells to present  GLPhe to B10.A(5R)  T  cells  (10,  42).  These 
results have been interpreted to indicate that  Ia antigens  are the lr gene products. 
The blocking data in the present experiments strongly support this hypothesis. 
Previous studies with radiation-induced bone marrow chimeras have suggested that 
anti-Ia sera inhibit antigen-presenting cell function (but not T  lymphocyte function) 
(43), and that both Ir gene products must be expressed in the antigen-presenting cell 
(but neither need be expressed in the T  lymphocyte) (44).  The demonstration in this 
paper that a  monoclonal antibody directed against an Ia determinant could inhibit 
T  cell  proliferation  in  an  antigen  specific  manner  (i.e.,  Y-17  blocks  the  GLPhe 
response  but  not  the  (T,G)-A--L response)  suggests  that  Ia-bearing  molecules  are 
indeed the structures whose function is being inhibited at the antigen-presenting cell 
surface. However, the possibility does remain that Ir and la loci are distinct but closely 
linked in the genome and that the products of these putative two loci are also closely LERNER, MATIS, JANEWAY, Jl~., JONES, SCHWARTZ, AND MURPHY  1099 
associated on the cell surface, such that anti-la antibody sterically interferes with Ir- 
gene function. The final proof that Ia antigens are indeed Ir gene products must await 
examination of I-region point mutations in which simultaneous changes in both Ia 
antigens and Ir-gene function are observed. 
Summary 
Genetic, biochemical, and functional studies have been performed using a  mono- 
clonal  antibody, Y-17,  directed  at  a  conformational or combinatorial  determinant 
formed by certain Ae:E~ complexes. This determinant appears to be a marker present 
on a  subset of B cells as well as on non-T and non-B spleen cells.  Besides A~ and E~ 
chains, Y-17 precipitates a  third chain that is indistinguishable from the A,, chain in 
two-dimensional gels. This result suggests additional combinatorial complexity in the 
generation of I-region encoded antigens.  Y-17 can inhibit  the response of T  cells  to 
A~:E~ determinants in mixed lymphocyte cultures. Furthermore, Y-17 blocks antigen- 
specific T  cell proliferative responses to GLPhe and pigeon cytochrome c which have 
been  shown  to  require  the  Ae:E~  complex  as  a  restriction  element  for  antigen 
presentation.  These results  provide strong evidence for the molecular identity of Ia 
antigens, Ir-gene products and Lad antigens. 
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